How often staging laparoscopy finds hidden spread in liver, pancreas, and bile duct cancers
Official title: To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies
Run by Institute of Liver and Biliary Sciences, India · NCT07480005 · Data updated 2026-11-12
This project will test whether staging laparoscopy still finds hidden metastases in people with suspected hepatopancreatobiliary cancers given modern imaging like CT, MRI, EUS, and PET-CT.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 350 (estimated) |
| Sponsor | Institute of Liver and Biliary Sciences, India Academic / other |
| Locations | 1 site (New Delhi, National Capital Territory of Delhi) |
| Status | Recruiting |
| Started | March 18, 2026 |
| Main results expected | October 30, 2026 |
| Study ends | October 30, 2026 |
| Registry record updated | March 23, 2026 |
| Trial ID | NCT07480005 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are patients with suspected HPB adenocarcinomas being considered for curative surgery who are scheduled for staging laparoscopy and have preoperative CT imaging with ≤1.5 mm slice thickness at ILBS, New Delhi.
✕Probably not a fit
Patients with non-adenocarcinoma tumors, those not undergoing surgery with curative intent, or those whose final diagnosis is benign would not be expected to benefit from this analysis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This ambispective cohort at the Institute of Liver & Biliary Sciences includes all patients who underwent staging laparoscopy for suspected hepatopancreatobiliary (HPB) malignancies from January 2012 to March 2026. The primary goal is to measure the yield of staging laparoscopy in detecting occult metastases, with secondary analyses of false positives/negatives, the incremental value of PET-CT over CT, and clinical or radiological predictors of findings. Eligible cases require preoperative CT scans with slice thickness ≤1.5 mm and exclude non-adenocarcinoma histologies, procedures without curative intent, and final benign histopathology.
Why it matters
Potential benefit: If successful, the results could help avoid unnecessary invasive procedures and guide surgeons on when staging laparoscopy is likely to change management.
How similar studies have gone: Earlier studies have shown that staging laparoscopy can detect occult metastases, but findings have been mixed and there is limited large-scale reappraisal in the era of modern high-resolution imaging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: \- All patients with suspected HPB malignancies undergoing staging laparoscopy before proceeding to laparotomy. Pre-op CT scans of cut size less than or equal to 1.5 mm Exclusion Criteria: 1. Patients undergoing staging laparoscopy without intent of curative resection in the same sitting. 2. malignancies other than adenocarcinoma 3. Final histopathology is benign
Where it's running
-
Institute of Liver and Biliary Sciences
New Delhi, National Capital Territory of Delhi, India Recruiting
Study contacts
- Study coordinator: Rahul Shivhare, MS
- Email: rahulshivhare93@gmail.com
- Phone: 01146300000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Comprehensive pre-surgery conditioning, with or without planned preoperative cancer therapy, before major abdominal or pelvic cancer operations.
This trial will test whether a comprehensive prehabilitation program, given alone or with planned neoadjuvant therapy, helps pre-frail or frail adults with pancreatic, ovarian, kidney, or bladder cancer better tolerate major cancer surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.